Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy for bladder cancer.

Cora N Sternberg1, Fabio Calabró

  • 1Department of Medical Oncology, San Camillo and Forlanini Hospitals, Nuovi Padiglioni IV Floor, Circonvallazione Gianicolense 87, 00152 Rome, Italy. cstern@mclink.it

Expert Review of Anticancer Therapy
|December 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.

European urology open science·2026
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Science advances·2026
Same author

Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literature.

JAMIA open·2026
Same author

Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy.

Clinical drug investigation·2026
Same author

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.

NPJ breast cancer·2026

Adjuvant chemotherapy after radical cystectomy for bladder cancer is not yet recommended. Current evidence from randomized trials is insufficient due to study limitations, necessitating larger trials for definitive conclusions.

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Radical cystectomy is a standard treatment for muscle-invasive bladder cancer.
  • Micrometastatic disease post-surgery contributes to treatment failure.
  • Adjuvant chemotherapy may offer survival benefits, similar to other cancers.

Purpose of the Study:

  • To evaluate the efficacy of adjuvant chemotherapy in bladder cancer patients.
  • To address deficiencies in existing studies on adjuvant chemotherapy.
  • To determine if current evidence supports routine use of adjuvant chemotherapy.

Main Methods:

  • Review of randomized trials evaluating adjuvant chemotherapy in pT3-pT4 and/or pN+ M0 bladder cancer.
  • Analysis of studies with limitations in sample size, statistical methods, and reporting.

Related Experiment Videos

  • Inclusion of a recent meta-analysis summarizing available evidence.

    • Main Results:

    • Existing studies on adjuvant chemotherapy have significant methodological deficiencies.
    • A recent meta-analysis found insufficient evidence to recommend adjuvant chemotherapy.
    • Current data does not reliably support adjuvant chemotherapy for bladder cancer.

    Conclusions:

    • Larger, well-designed randomized trials are required to establish the role of adjuvant chemotherapy.
    • Definitive conclusions cannot be drawn from the current body of evidence.
    • Adjuvant chemotherapy is not reliably recommended for bladder cancer patients post-cystectomy at this time.